

Press Release

Zug, 27 July 2010

HBM BioVentures Quarterly Report as at 30 June 2010

HBM BioVentures closed the first three months (1 April to 30 June 2010) of the current financial year 2010/2011 with a net asset value (NAV) per share of CHF 65.00 (-1.3 %). There were no major changes to the valuations of the investment holdings. HBM BioVentures maintains appropriate levels of liquidity even after the full repayment of the convertible bond in April 2010. Following the liquidity injection of CHF 11.5 million as a result of the sale of the USD hedging position, cash and cash equivalents now stand at more than CHF 40 million. HBM BioVentures could also raise over CHF 50 million more by selling investments in public companies, including the position in Micrus, which was acquired by Johnson & Johnson.

Private companies in the portfolio

A concerted effort is being made with regard to the sale of several private portfolio companies. Some of these processes are already at the negotiation stage. HBM BioVentures continued to support a number of companies in the portfolio with follow-on financings of approximately CHF 13 million.

Investment portfolio

Just under 80% of HBM BioVentures' current investment portfolio is composed of positions in private companies, more than half of which (in terms of scope of investment) are operating profitably or already selling products on the market. 58% of the portfolio is held in USDollars (after the USDollar hedge was sold on 2 July 2010). Investment holdings in Euros (24%) and Swiss francs (15%) account for the rest of the portfolio. Foreign exchange risks are not hedged at present. Investments in public companies have been trimmed back a little further.

Outlook

Several of HBM BioVentures' companies in the portfolio are currently in negotiations on either a trade sale or an alliance with a larger partner in the industry. We anticipate that a few of these negotiations will conclude in successful deals over the coming six to nine months. These transactions should increase HBM BioVentures' net asset value and generate liquidity. The operating businesses of our more mature portfolio companies are developing well, and our research companies are also making good progress with their clinical trials. These advances underscore not only the value and stability of the investment portfolio, but also the prospects of emerging companies that are still at the development stage.

NOT FOR DISTRIBUTION IN THE USA, CANADA, JAPAN OR AUSTRALIA

HBM BioVentures

The quarterly report as at 30 June 2010 is available on the web site of HBM BioVentures Ltd. www.hmbioventures.com.

For further information, please contact Dr. Andreas Wicki, CEO HBM BioVentures Ltd, tel.: +41 41 768 11 08, andreas.wicki@hmbioventures.com.

Brief profile of HBM BioVentures Ltd

As a venture capital company, HBM BioVentures invests world-wide in some 35 mature young companies in the biotechnology/human medicine, diagnostics and medical technology sectors. The primary products of many of HBM BioVentures' portfolio companies are either at an advanced stage of development or already available on the market. The company focuses on unlisted emerging companies. Two thirds of investment capital is invested in private companies with high value creation potential. This has enabled HBM BioVentures to carve out a unique and distinctive market position. HBM BioVentures has a broad shareholder base and is listed on the SWX Swiss Exchange (ticker: HBMN).

Disclaimer

This media release does not constitute an issue prospectus within the meaning of Art. 652a or Art. 1156 of the Swiss Code of Obligations, a listing prospectus in the sense of the SIX Swiss Exchange Listing Rules or a securities prospectus as defined in the German Securities Prospectus Act (*Wertpapierprospektgesetz*). Publication is for information purposes only and constitutes neither an offer to sell nor an invitation to buy or subscribe for securities. This media release and the information it contains must not be distributed or forwarded to or within the United States of America (USA) or to US persons (including legal entities) or publications with a general circulation in the USA. This media release does not constitute an offer or invitation to purchase any securities in the USA. The securities of HBM BioVentures Ltd have not been registered under United States securities legislation and may not be offered, sold or delivered within the USA or to US persons without prior registration or the corresponding exemption from the registration requirements of US securities legislation.

HBM BioVentures Ltd
Bundesplatz 1
CH-6300 Zug/ Switzerland
Tel:+41 41 768 11 08
Fax:+41 41 768 11 09
info@hmbioventures.com
www.hmbioventures.com